RhumbLine Advisers
CATX icon

RhumbLine Advisers’s Perspective Therapeutics CATX Stock Holding History

RhumbLine Advisers’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
123,299
+46,209
+60% +$175K ﹤0.01% 2875
2026
Q1 		$321K Buy
77,090
+519
+0.7% +$2.19K ﹤0.01% 2882
2025
Q4 		$211K Sell
76,571
-8,234
-10% -$23.5K ﹤0.01% 3158
2025
Q3 		$291K Buy
84,805
+1,555
+2% +$5.67K ﹤0.01% 3021
2025
Q2 		$286K Sell
83,250
-14,912
-15% -$39.4K ﹤0.01% 3011
2025
Q1 		$209K Buy
98,162
+3,170
+3% +$9.51K ﹤0.01% 3082
2024
Q4 		$303K Buy
94,992
+4,075
+4% +$33.3K ﹤0.01% 2979
2024
Q3 		$1.21M Buy
90,917
+27,747
+44% +$369K ﹤0.01% 2164
2024
Q2 		$630K Buy
+63,170
New +$913K ﹤0.01% 2508

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

RhumbLine Advisers's CATX Position: Q2 2026 in Review

RhumbLine Advisers increased its Perspective Therapeutics (CATX) stake by 60% in Q2 2026, buying an estimated $175K and bringing the position to 123,299 shares worth $420K. The position accounts for ﹤0.01% of the portfolio, ranked #2875.

RhumbLine Advisers first reported a position in CATX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.21M in Q3 2024. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • RhumbLine Advisers held 123,299 shares of Perspective Therapeutics worth $420K as of Q2 2026.
  • RhumbLine Advisers bought 46,209 Perspective Therapeutics shares in Q2 2026, an estimated $175K.
  • Perspective Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2875 holding.
  • RhumbLine Advisers first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • RhumbLine Advisers's Perspective Therapeutics position peaked at $1.21M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.